Omics Insights Into Cancer Histology; Metabolomics and Proteomics Approach Publisher Pubmed



Tayanloobeik A¹ ; Sarvari M² ; Payab M³ ; Gilany K^{4, 5} ; Alavimoghadam S¹ ; Gholami M⁶ ; Goodarzi P⁸ ; Larijani B⁹ ; Arjmand B^{1, 2} Show Affiliations
Source: Clinical Biochemistry Published:2020

Abstract

Metabolomics as a post-genomic research area comprising different analytical methods for small molecules analysis. One of the underlying applications of metabolomics technology for better disease diagnosis and prognosis is discovering the metabolic pathway differences between healthy individuals and patients. On the other hand, the other noteworthy applications of metabolomics include its effective role in biomarker screening for cancer detection, monitoring, and prediction. In other words, emerging of the metabolomics field can be hopeful to provide a suitable alternative for the common current cancer diagnostic methods especially histopathological tests. Indeed, cancer as a major global issue places a substantial burden on the health care system. Hence, proper management can be beneficial. In this respect, formalin-fixed paraffin-embedded tissue specimens (in histopathological tests) are considered as a valuable source for metabolomics investigations. Interestingly, formalin-fixed paraffin-embedded tissue specimens can provide informative data for cancer management. In general, using these specimens, determining the cancer stage, individual response to the different therapies, personalized risk prediction are possible and high-quality clinical services are the promise of OMICS technologies for cancer disease. However, considering all of these beneficial characteristics, there are still some limitations in this area that need to be addressed in order to optimize the metabolomics utilizations and advancement. © 2020 The Canadian Society of Clinical Chemists